The clinical management of low level viremia (LLV) remains unclear. The objective of this study was to investigate the association of blips and LLV with virologic failure.
We enlisted patients who newly enrolled into the HIV Research Network between 2005-2015, had HIV-1 RNA >200 c/mL, and were either ART-naïve or ART-experienced and not on ART. Patients were included who achieved virologic suppression (≤ 50 on two consecutive viral loads) and had ≥ 2 viral loads following suppression. Blips and LLV (≥ 2 consecutive > 51 c/mL) were categorized separately into 3 categories: no blips/LLV, 51-200, 201-500. Cox proportional hazards regression was used to assess association between rates of blips/LLV and virologic failure (two consecutive >500).
The 2795 patients were mostly male (75.4%), black (50.3%), and MSM (52.9%). Median age was 38 years old (IQR 29-48). Most patients (88.8%) were ART-naïve at study entry. Overall, 283 (10.1%) patients experienced virologic failure. A total of 152 (5.4%) patients experienced LLV to 51-200 and 110 (3.9%) patients experienced LLV to 201-500. Both LLV 51-200 (aHR 1.83 [1.10,3.04]) and LLV 201-500 (aHR 4.26 [2.65,6.86]) were associated with virologic failure. In sensitivity analysis excluding ART experienced patients, the association between LLV51-200 and virologic failure was not statistically significant.
LLV between 201-500 was associated with virologic failure, as was LLV between 51-200, particularly among ART experienced patients. Patients with LLV below the current DHHS threshold for virologic failure (persistent viremia ≥ 200) may require more intensive monitoring because of increased risk for virologic failure.
aJohns Hopkins University School of Medicine, Baltimore, MD
bUniversity of California San Diego, San Diego, CA
cChildren's Hospital of Philadelphia, Philadelphia, PA
dIcahn School of Medicine at Mt Sinai, New York, NY, USA
eUniversity of South Florida, Tampa, FL
fHealth Resources and Services Administration, Rockville, MD.
Correspondence to Julia Fleming, Johns Hopkins University School of Medicine, Baltimore, Maryland UNITED STATES; e-mail: firstname.lastname@example.org
Received 4 January, 2019
Revised 10 April, 2019
Accepted 11 April, 2019